We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Celadon Pharmaceuticals Plc | CEL | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 15.00 | 08:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 15.00 | 15.00 | 15.00 | 15.00 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 06/12/2024 08:20 by zen12 £1.05/share investor knows what this is worth...happy to subscribe at this price when share price is 16p...tells you all that you need to know. Very positive news. |
Posted at 22/5/2024 20:02 by czar Its funny investors keep committing money at above the market price when the vast majority have to raise at huge discounts. Somebody can see a big return here, could they be right? |
Posted at 10/5/2024 06:59 by czar These new investors want in to CEL and are happy to pay the offer price, that speaks volumes for what they know about this business. |
Posted at 16/11/2023 07:38 by ahhh luke warm Let's see if that adds more to the 135mlnMC. Jak, probably spot on with the shorting MM investor. What's your thoughts around John Gunn and GIS? |
Posted at 16/11/2023 07:31 by ahhh luke warm Financing unsecured CLNs at 10% interest. The last line is a red flag to this sort of set up. Mr Short came over all holy and clean and crisp but now associated with John Gunn financing. Tut, tut!At this stage it is anticipated that the Convertible Loan Notes will be issued at par with a 5 year term and will be unsecured. The notes are expected to carry a coupon of 10 per cent. per annum and to be convertible at the option of the investor after 2 years, or to be mandatorily converted into ordinary shares of 1 pence each ("Ordinary Shares") on a qualifying financing to be determined or change of control of the Company. |
Posted at 16/11/2023 07:24 by ahhh luke warm Jak, never a good sign unless it's for him where a John Gunn company appear in association; ie: GISFrom the raise RNS:The Company is also pleased to announce the appointment of Global Investment Strategy UK Limited as Joint Broker to the Company. Canaccord Genuity Limited will remain as NOMAD and a Broker to the Company.Future Convertible Loan NotesIn addition to the Fundraise above and following investor interest, the Company is seeking to raise further funding moving forward through the issuance of Convertible Loan Notes ("CLN Financing"). The Company has already received expressions of interest from potential investors to subscribe for the CLN Financing. |
Posted at 13/10/2023 09:07 by jaknife Who are these supposed "serious investors"? I assumed that it was the market maker that took up the placing after having gone short into the market for the previous six months!There are no "serious investors" investing into Celadone. It's a loss-making, cash-burning spin machine and has net assets of just £3m. Yet the market cap is £77m! People are paying £77m to buy £3m of assets, that's like paying £25 to buy a used £1 coin! |
Posted at 13/10/2023 07:25 by czar Serious investors just paid 125p when the morons were selling it at 115p, who is smarter, who knows more? I'm following the intelligent investors money and adding at 125p. |
Posted at 16/3/2023 10:01 by czar There clearly are very few private investors involved in CEL, several are using this thread to promote other stocks but none of these have the Home Office Licence. The truth is only a handful of companies worldwide can supply medical-grade cannabis to the pharmaceutical industry, this is an extremely valuable Company IMHO. Celadon will almost certainly receive a take over approach, its a question of WHEN not IF. The big question is at what level a bid will come in at and what would the management accept? GW Pharma gives a great clue as to the sort of number we can expect." -- Receipt of updated Home Office licence enables Celadon to commence the commercial supply of its GMP pharmaceutical cannabis product -- GMP registration is understood to be the first such registration of a UK pharmaceutical facility for high THC cannabis active pharmaceutical ingredient ("API") since the legalisation of medical cannabis in 2018 -- GMP registration and a Home Office licence are required in order to sell high-THC medicinal cannabis in the UK -- Celadon becomes one of a small number of companies globally with the capability to produce an EU-GMP grade high-THC cannabinoid API" |
Posted at 10/8/2011 09:24 by chaka Caparo Energy Limited("Caparo Energy" or the "Company") Caparo Energy closes second tranche of Mezzanine Further orders placed with Suzlon Directorate changes Notice of EGM Closed Second Tranche of Mezzanine: The Board of Directors of Caparo Energy (the "Board") is pleased to announce that Caparo Energy (India) Limited ("CEIL"), the Company's wholly owned subsidiary, has closed a second tranche of mezzanine funding. This second tranche of mezzanine financing, which is for a 4 year term, of Rs. 1,500m (US$33.5m) is being provided by the Infrastructure Development Finance Company Limited ("IDFC"). As stated in the Company's previous announcement of 20 June 2011, the terms of both tranches of mezzanine financing entail no equity dilution for Caparo Energy's existing shareholders. The Board believes that this will result in enhanced equity returns for investors. The Company expects to repurchase/buy-back both tranches of mezzanine from internal cash flows and the issue of senior debt instruments, bonds or other debt refinancing, within three to five years. The Board believes that securing these two tranches of financing, totalling Rs 5,000 (US$112m), is a significant step forward for the business and anticipates that this additional funding, along with the Company's existing resources, would enable the Company to develop approximately 700 MW of wind projects. Purchase orders for 260 MW placed with Suzlon Since our previous announcement, CEIL has placed specific purchase orders with Suzlon Energy Limited ("Suzlon") for a further 260 MW of wind projects for delivery by March 2012. When combined with the 100 MW ordered in February 2011, CEIL's total purchase orders have grown to 360 MW, of which 52 MW have already been commissioned, with the balance expected to be commissioned in stages by March 2012. The Company will release further updates of orders being placed for delivery by March 2012 in due course. The new purchase orders for 260 MW cover five individual projects located in the states of Maharashtra, Gujarat, Karnataka and Rajasthan. All of these sites have wind data using a met mast measured at different heights for an average period of over four years and are fully permitted. The Company has selected these sites based on detailed analysis and independent wind studies completed by internationally recognised firms in this field, and the Board is confident that these projects represent some of the best sites being commissioned in India over the next two years and that the Plant Load Factors ("PLF") for these sites are very attractive. Following the placing of these orders, which are ahead of the schedule previously announced, the Board anticipates that by March 2012 the Company will have a total of 500 MW of fully operational projects connected to the grid and generating cash flow. Additionally, the Board expects to achieve the full 1 GW of project orders with Suzlon by March 2013. Management Team of CEIL CEIL has been building its management team and would like to report that it has identified and recruited certain key personnel to further execute the Company's strategy: R. Ramakrishnan has been appointed as President of CEIL. Prior to this appointment, he was CEO/Managing Director at GMR Industries (GMR Group is a diversified infrastructure group in India with interests in power, airports and roads) for four years before becoming Group Corporate Head of its Renewable Energy business. Previously, he was the Chief Executive of Sanmar Group and, prior to that, was with the Murugappa Group for 20 years where he worked in Sales & Marketing, International Business Development, Product Management, Manufacturing & Technical services. CEIL has also made a number of hires in various departments across the company including wind resources, project planning and execution, finance, legal and operations and maintenance, as it continues to look towards the Company's progressive growth for the future. Directorate changes The Company would also like to report changes in the composition of the Board: Angad Paul, CEO of the Caparo Group, is stepping down from his current role as Non-Executive Chairman of the Company and will continue as a Non-Executive Director. Accordingly, Ravi Kailas has been appointed Chairman of the Company, in addition to his current role as CEO of the Company. In addition, Charles Wilkinson, Independent Non-Executive Director of the Company based in Guernsey, will not be standing for re-election at the forthcoming AGM. In light of these developments, the Company intends to appoint two additional independent Non Executive Directors to the Board in due course. Notice of EGM The Board announces that a circular containing a notice of Extraordinary General Meeting ("EGM"), to be convened for 5 September 2011, at 10 a.m at Anson Place, Mill Court, La Charroterie, St Peter Port, Guernsey, GY1 1EJ, Channel Islands, is today being sent to shareholders. The purpose of the EGM is to seek shareholder approval to update the relevant Board authorities to issue shares and dis-apply pre-emption rights and to change the name of the Company from Caparo Energy Limited to Mytrah Energy Limited. The notice of EGM and form of proxy, together with an explanatory covering letter from the Chairman and Chief Executive Officer, is being posted to shareholders today and will shortly be made available on the Company's website at www.caparoenergy.com Ravi Kailas, Caparo Energy's Chairman and Chief Executive Officer, commented: "The closing of the second tranche of mezzanine financing in a timely manner puts our company in a position to fund over 700 MW of wind projects without any dilution to existing shareholders. We are also pleased with the strengthening of our management team with people who have a proven track record in the industry. By placing 360 MW of orders with Suzlon for delivery by March 2012, the Company demonstrates again its ability to build utility scale wind power projects with an unprecedented efficiency. "As the Company's transformative growth continues, its identity has also evolved. Accordingly, the Company is proposing to change it's name to Mytrah Energy Limited and we are excited by the Company's prospects of trading under this new identity. The Board would like to re-iterate its gratitude to have begun as Caparo Energy and would like to thank the Caparo Group for their on-going support to the Company." Further information on the Company can be found at www.caparoenergy.com |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
